Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Cytokinetics Partners with Sanofi To Develop Aficamten in Greater China
Details : Sanofi will acquire CORXEL’s rights relating to CK-3773274 (aficamten) in Greater China> It is being evaluated for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy.
Brand Name : CK-3773274
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 20, 2024
Lead Product(s) : Aficamten
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?